The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Predictive power of hepatitis B 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China.
Alvaro Muñoz; Jian Guo Chen; Patricia A Egner; Melinda L Marshall; Jamie L Johnson; Michael F Schneider; Jian Hua Lu; Yuan Rong Zhu; Jin-Bing Wang; Tao Yang Chen; et al. (Profiled Authors: Patricia Egner; John Groopman; Thomas Kensler; Alvaro Munoz)
Johns Hopkins University Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA.
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with nearly 700,000 deaths occurring annually. Hepatitis B virus (HBV) is a major contributor to HCC and acquired mutations in the HBV genome may accelerate its pathogenesis. In this study, a matched case-control investigation of 345 men who died of HCC and 625 controls were nested within a cohort of male hepatitis B surface antigen (HBsAg) carriers from Qidong, China. Matched preserving odds ratios (ORs) were used as a measure of association and 95% confidence intervals (CIs) as a measure of precision. Real-time polymerase chain reaction allowed for a quantitative comparison of the levels of the HBV 1762(T)/1764(A) mutation in cases and controls. A total of 278 (81%) of the cases were positive for the HBV 1762(T)/1764(A) mutation compared with 250 (40%) of the controls. The matched preserving OR of 6.72 (95% CI: 4.66 to 9.68) strongly indicated that cases were significantly more probably than controls to have the mutation. Plasma levels of DNA harboring the HBV mutation were on average 15-fold higher in cases compared with controls (P < 0.001). Most strikingly, the level of the mutation in the 20 controls who later developed and died of HCC were on average 274-fold higher than controls who did not develop HCC. Thus, within this cohort of HBsAg carriers at high risk of developing HCC, individuals positive for the HBV 1762(T)/1764(A) mutation at enrollment were substantially more probably to subsequently develop HCC, with a higher concentration of the mutation in plasma enhancing predisposition for cancer development.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Hwai-I Yang; Shiou-Hwei Yeh; Pei-Jer Chen; Uchenna H Iloeje; Chin-Lan Jen; Jun Su; Li-Yu Wang; Sheng-Nan Lu; San-Lin You; Ding-Shinn Chen; et al.Journal of the National Cancer Institute 2008;100(16):1134-43.
Jin-De Chen; Hwai-I Yang; Uchenna H Iloeje; San-Lin You; Sheng-Nan Lu; Li-Yu Wang; Jun Su; Chien-An Sun; Yun-Fan Liaw; Chien-Jen Chen; et al.Gastroenterology 2010;138(5):1747-54.
Chih-Feng Wu; Ming-Whei Yu; Chih-Lin Lin; Chun-Jen Liu; Wei-Liang Shih; Keh-Sung Tsai; Chien-Jen ChenCarcinogenesis 2008;29(1):106-12.
Appears in this Publication
Author of this Publication